Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

CIK 00019033606 companiesBOSTON, MA

Transactions

Companies

Filings

CIK

0001903360

Recent Transactions

15 trades

Conversion
Avalyn Pharma Inc.$AVLN
Series D Convertible Preferred Stock
2026-05-01−4,060,259→ 0 total
Conversion
Avalyn Pharma Inc.$AVLN
Series C-1 Convertible Preferred Stock
2026-05-01−20,482,289→ 0 total
Conversion
Avalyn Pharma Inc.$AVLN
Common Stock
2026-05-01+1,275,486→ 1,275,486 total
Conversion
Metsera, Inc.$MTSR
Series B Preferred Stock
2025-01-30−4,365,079→ 0 total
Conversion
Metsera, Inc.$MTSR
Common Stock
2025-01-30+1,857,699→ 1,857,699 total
Conversion
Upstream Bio, Inc.$UPB
Common Stock
2024-10-15+894,733→ 894,733 total
Conversion
Upstream Bio, Inc.$UPB
Series B redeemable convertible preferred stock
2024-10-15−852,940→ 0 total
Conversion
MBX Biosciences, Inc.$MBX
Series C Preferred Stock
2024-09-16−4,854,368→ 0 total
Conversion
MBX Biosciences, Inc.$MBX
Series B Preferred Stock
2024-09-16−16,666,666→ 0 total
Conversion
MBX Biosciences, Inc.$MBX
Common Stock
2024-09-16+403,787→ 1,790,122 total
Conversion
MBX Biosciences, Inc.$MBX
Common Stock
2024-09-16+1,386,335→ 1,386,335 total
Conversion
CARGO Therapeutics, Inc.
Series A-1 Preferred Stock
2023-11-14−10,000,000→ 0 total
Conversion
CARGO Therapeutics, Inc.
Common Stock
2023-11-14+737,000→ 737,000 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+1,557,846→ 1,557,846 total
Conversion
RayzeBio, Inc.
Series D Preferred Stock
2023-09-19−1,557,846→ 0 total

C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET

BOSTON, MA, 02210